ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial
Temsunaro Rongsen Chandola, Sunita Taneja, Nidhi Goyal, Kalpana Antony, Kiran Bhatia, Deepak More, Nita Bhandari, Iksung Cho, Krishna Mohan, Sai Prasad, Gvja Harshavardhan, Tataji Surender Rao, Sudhanshu Vrati, Maharaj Kishan Bhan, Temsunaro Rongsen Chandola, Sunita Taneja, Nidhi Goyal, Kalpana Antony, Kiran Bhatia, Deepak More, Nita Bhandari, Iksung Cho, Krishna Mohan, Sai Prasad, Gvja Harshavardhan, Tataji Surender Rao, Sudhanshu Vrati, Maharaj Kishan Bhan
Abstract
A phase III randomized double-blind placebo-controlled trial was conducted in the urban neighborhoods of Delhi to assess whether Oral Rotavirus Vaccine ROTAVAC® interferes with the immune response to childhood vaccines when coadministered. Infants aged 6 weeks were randomized to receive three doses of either ROTAVAC® or placebo along with childhood vaccines: Oral Polio Vaccine and vaccines against Diphtheria, Pertussis, Tetanus, Hepatitis B and Haemophilus influenza type b given as Pentavalent at 6, 10, 14 weeks of age. Blood specimens were collected from all infants at baseline and 4 weeks post dose 3 to assess the immune response to antigens in Oral Polio Vaccine, Pentavalent and ROTAVAC® vaccines. Non-inferiority of immune response to all vaccine components of the childhood vaccines when ROTAVAC® was administered concurrently was demonstrated. Non-inferior immune responses to childhood vaccines were evaluated based on the seroprotective levels of antibodies against polio types 1, 2, and 3, Diphtheria toxoid, Tetanus toxoid, Haemophilus influenza type b anti- polyribosyl ribitol phosphate antibodies and Hepatitis B antibodies; and the Geometric Mean Concentration for Pertussis. The proportion of infants who seroconverted (≥4 fold rise) was 38.6% in the ROTAVAC® group and 12.2% in the placebo group. The frequency and severity of immediate adverse events, adverse events and serious adverse events were similar in both groups. None of the five reported deaths were considered to be related to the ROTAVAC® and no case of intussusception meeting Brighton Diagnostic Certainty Level I criteria was reported. This study demonstrated that ROTAVAC® can be safely administered with childhood vaccines without interfering with the immune response to the antigens contained in these vaccines.
Keywords: Immunology; Infectious disease; Pediatrics; Vaccines.
Figures
References
- The WHO position paper on rotavirus vaccines Wkly. Epidemiol. Rec. 2013;88:49–64.
- Bhan M.K., Glass R.I., Ella K.M., Bhandari N., Boslego J., Greenberg H.B. Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. Lancet. 2014;383:2180–2183.
- Bhandari N., Sharma P., Glass R.I., Ray P., Greenberg H., Taneja S. Safety and Immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321in infants: Results of a randomized controlled trial. Vaccine. 2006;24:5817–5823.
- Bhandari N., Sharma P., Taneja S., Kumar T., Rongsen-Chandola T., Appaiahgari M.B. A Dose-Escalation Safety and Immunogenicity Study of Live Attenuated Oral Rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Infect. Dis. 2009;200:421–429.
- Bhandari N., Rongsen-Chandola T., Bavdekar A., John J., Antony K., Taneja S. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomized, double-blind, placebo-controlled trial. Lancet. 2014;383:2136–2143.
- Government of India Ministry of Health and Family Welfare. Universal Immunization Program. (accessed Jun 18, 2016)
- Government of India The Drugs and Cosmetics Act and Rules: The Drugs and Cosmetics Act, 1940 (as amended up to the 30th June, 2005) (accessed Jun 18, 2016)
- Indian Council of Medical Research Ethical Guidelines for Biomedical Research on Human Participants, 2006. (accessed Jun 18, 2016)
- Bahl R., Bhandari N., Kant S., MØlbak K., Østergaard E., Bhan M.K. Effect of vitamin A administered at expanded program on immunization contact on antibody response to oral polio vaccine. Eur. J. Clin. Nutr. 2002;56:321–325.
- Plotkin A.S. Vaccines: Correlates of Vaccine-Induced Immunity. Clin. Infect. Dis. 2008;47:401–409.
- Ali S.S., Chandrashekar S.R., Singh M., Bansal R.K., Sharma D.R., Arora D. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine) Hum. Vaccin. 2007;3:116–120.
- Bavdekar S.B., Maiya P.P., Subba Rao S.D., Datta S.K., Bock H.L. Immunogenicity and safety of combined diphtheria-tetanus whole cell pertussis Hepatitis B/Haemophilus influenzae type b vaccine in Indian infants. Indian Pediatr. 2007;44:505–510.
- Ward R.L., Bernstein D.I., Shukla R., Young E.C., Sherwood J.R., McNeal M.M. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J. Infect. Dis. 1989;159:79–88.
- Bines J.E., Kohl K.S., Forster J., Zanardi L.R., Davis R.L., Hansen J. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine. 2004;22:569–574.
- Gart J.J., Nam J. Approximate Interval Estimation of the Difference in Binomial Parameters: Correction for Skewness and Extension to Multiple Tables. Biometrics. 1990;46:637–643.
Source: PubMed